Study suggests statins reduce cardiovascular risk for people with type 2 diabetes (p 641, 685)August 18, 2004Results of a randomised trial in this week's issue of THE LANCET suggest that people with type 2 diabetes could benefit from cholesterol-lowering therapy with statins to reduce the risk of cardiovascular disease-even when they do not have high cholesterol concentrations. Many recent studies have shown the benefits of statin therapy to reduce the risk of cardiovascular disease in various groups of patients. Whether most patients with diabetes (who are known to be at increased cardiovascular risk) should receive cholesterol-lowering therapy remains unclear, especially for those patients who do not have High cholesterol. Helen Colhoun (University College Dublin, Ireland, formerly at University College London ) and colleagues assess the effectiveness of atorvastatin for the primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of LDL-('bad') cholesterol. Around 2800 patients (aged 40-75 years) in 132 centres in the UK and Ireland were randomly assigned either placebo (1410 patients) or atorvastatin (1428 patients). Patients had no previous history of cardiovascular disease and had low LDL cholesterol concentrations (around 4 millimoles per litre or less). Average follow-up was around 4 years after study enrolment. The primary outcome measure of the study-acute coronary heart disease events, coronary revascularisation, or stroke-was reduced by around a third among patients given atorvastatin compared with those given placebo. Atorvastatin reduced the death rate by 27% compared with placebo. Strokes were reduced by 48%. Professor Colhoun comments: Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovascular disease events, including stroke, in patients with type 2 diabetes without high LDL-cholesterol. No justification is available for having a particular threshold level of LDL-cholesterol as the sole arbiter of which patients with type 2 diabetes should receive statins. The debate about whether all people with this disorder warrant statin treatment should now focus on whether any patients are at sufficiently low risk for this treatment to be withheld. In an accompanying commentary (p 641), Abhimanyu Garg (University of Texas, USA) concludes: "While landmark trials like CARDS increase our confidence in lipid-lowering drug therapy for prevention of coronary heart disease in patients with type 2 diabetes, it is still prudent to assess an individual's risk-benefit ratio before recommending long-term statin therapy. Thus more models need to be developed, such as the UK Prospective Diabetes Study risk engine, to assess coronary heart disease risk in patients with type 2 diabetes. For patients with type 2 diabetes at moderate to low risk of coronary heart disease, maximal lowering of lipids with diet, exercise, weight loss, and rigorous glycaemic control must be attempted before considering lipid-lowering drugs". | |||||||||||||||||||||
|
Related Diabetes Current Events and Diabetes News Articles Obesity: Reviving the promise of leptin The discovery more than a decade ago of leptin, an appetite-suppressing hormone secreted by fat tissue, generated headlines and great hopes for an effective treatment for obesity. Substance abuse adds millions to Medicaid's total health care costs People with substance abuse disorders cost Medicaid hundreds of millions of dollars annually in medical care, suggesting that early interventions for substance abuse could not only improve outcomes but also save substantial amounts of money, according to a comprehensive study that examined records of nearly 150,000 people in six states. Low-carb diets prove better at controlling type 2 diabetes In a six-month comparison of low-carb diets, one that encourages eating carbohydrates with the lowest-possible rating on the glycemic index leads to greater improvement in blood sugar control, according to Duke University Medical Center researchers. Understanding Extinct Microbes May Influence the State of Modern Human Health The study of ancient microbes may not seem consequential, but such pioneering research at the University of Oklahoma has implications for the state of modern human health. Cecil Lewis, assistant professor in the Department of Anthropology, says results of this research raise questions about the microbes living on and within people. Smokers with stroke in the family 6 times more likely to have stroke too A new study shows that people who are smokers and have a family history of brain aneurysm appear to be significantly more likely to suffer a stroke from a brain aneurysm themselves. Researchers engineer pancreatic cell transplants to evade immune response In a finding that could significantly influence the way type 1 diabetes is treated, researchers at Albert Einstein College of Medicine of Yeshiva University have developed a technique for transplanting insulin-producing pancreatic cells that causes only a minimal immune response in recipients. Antioxidants offer pain relief in patients with chronic pancreatitis Antioxidant supplementation was found to be effective in relieving pain and reducing levels of oxidative stress in patients with chronic pancreatitis (CP), reports a new study in Gastroenterology. University of Maryland researchers identify common gene variant linked to high blood pressure Researchers at the University of Maryland School of Medicine have identified a common gene variant that appears to influence people's risk of developing high blood pressure, according to the results of a study being published online Dec. 29, 2008 in the Proceedings of the National Academy of Sciences (PNAS). Researchers at Columbia University Medical Center link blood sugar to normal cognitive aging Maintaining blood sugar levels, even in the absence of disease, may be an important strategy for preserving cognitive health, suggests a study published by researchers at Columbia University Medical Center (CUMC). The study appeared in the December issue of Annals of Neurology. Minimizing obesity's impact on ovarian cancer survival Obesity affects health in several ways, but new research shows obesity can have minimal impact on ovarian cancer survival. A study by researchers at the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center found ovarian cancer survival rates are the same for obese and non-obese women if their chemotherapy doses are closely matched to individual weight. More Diabetes Current Events and Diabetes News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||